Rahul Lakhotia
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rahul Lakhotia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:51 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05211336 · Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemNational Cancer Institute (NCI) · active not recruiting · Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS · principal investigator
- Ph2NCT03964090 · Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)National Cancer Institute (NCI) · active not recruiting · Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma · principal investigator
- Ph2NCT03789240 · Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaNational Cancer Institute (NCI) · active not recruiting · Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL · principal investigator
- N/ANCT03190928 · Clonal Evolution in Follicular LymphomaNational Cancer Institute (NCI) · recruiting · Follicular Lymphoma · principal investigator
- Ph1NCT02203526 · Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS LymphomaNational Cancer Institute (NCI) · active not recruiting · Primary Central Nervous System Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:51 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.N Engl J Med · 202473 citationsRCR 8.2
- 44 citationsRCR 2.9
- Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.Blood Adv · 202120 citationsRCR 1.1
- A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.Blood Neoplasia · 20244 citationsRCR 0.4
- Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.Leuk Lymphoma · 20250 citationsRCR 0.0